Company intelligence / Profile preview

Future Biome

Buenos Aires, Argentinafuturebiome.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Their first development, the microbial functional booster (MFB), a fungal carbohydrate, increased the production of microbial anti-inflammatory molecules up to 500%, and was 100% effective in their in vitro study. Scalability and clinical validation are in progress[5].

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Fungal-based prebioticsmicrobiota nutrition
Industry: Food & Nutrition

Drug pipeline

1 asset

BiotaBliss

Phase 2

Indications: Gut inflammation, Immune system disorders

Partnerships

Biomill (Spin off Pharma Lab Argentina)Biogaia (Biopharma Lab Sweden)ENA (nutrition supplement company Argentina)[3]

Beyond the preview

Go deeper on Future Biome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Future Biome.

Explore the full profile